ZA200202175B - Use of an outer membrane protien a of an enterobacterium associated with a RSV immunogenic peptide for preparing vaccines for intranasal administration. - Google Patents

Use of an outer membrane protien a of an enterobacterium associated with a RSV immunogenic peptide for preparing vaccines for intranasal administration.

Info

Publication number
ZA200202175B
ZA200202175B ZA200202175A ZA200202175A ZA200202175B ZA 200202175 B ZA200202175 B ZA 200202175B ZA 200202175 A ZA200202175 A ZA 200202175A ZA 200202175 A ZA200202175 A ZA 200202175A ZA 200202175 B ZA200202175 B ZA 200202175B
Authority
ZA
South Africa
Prior art keywords
enterobacterium
protien
outer membrane
intranasal administration
immunogenic peptide
Prior art date
Application number
ZA200202175A
Other languages
English (en)
Inventor
Nathalie Corvaia
Liliane Goetsch
Original Assignee
Pf Medicament
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pf Medicament filed Critical Pf Medicament
Publication of ZA200202175B publication Critical patent/ZA200202175B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6068—Other bacterial proteins, e.g. OMP
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18522—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
ZA200202175A 1999-09-23 2002-03-18 Use of an outer membrane protien a of an enterobacterium associated with a RSV immunogenic peptide for preparing vaccines for intranasal administration. ZA200202175B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9911888A FR2798857B1 (fr) 1999-09-23 1999-09-23 Utilisation d'une proteine de membrane ompa d'enterobacterie associee a un peptide immunogene du vrs pour la preparation de vaccins administrables par voie nasale

Publications (1)

Publication Number Publication Date
ZA200202175B true ZA200202175B (en) 2002-12-24

Family

ID=9550162

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200202175A ZA200202175B (en) 1999-09-23 2002-03-18 Use of an outer membrane protien a of an enterobacterium associated with a RSV immunogenic peptide for preparing vaccines for intranasal administration.

Country Status (10)

Country Link
EP (1) EP1218029A1 (ja)
JP (1) JP2003528812A (ja)
CN (1) CN1379682A (ja)
AU (1) AU7530100A (ja)
BR (1) BR0014246A (ja)
CA (1) CA2385404A1 (ja)
FR (1) FR2798857B1 (ja)
MX (1) MXPA02003132A (ja)
WO (1) WO2001021203A1 (ja)
ZA (1) ZA200202175B (ja)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2827605B1 (fr) 2001-07-20 2004-07-16 Pf Medicament Nouveaux peptides derives de la proteine g du vrs et leur utilisation dans un vaccin
FR2828106A1 (fr) * 2001-08-02 2003-02-07 Pf Medicament Utilisation d'une omp d'enterobacterie de faible masse moleculaire comme porteur et/ou adjuvant
US7507809B2 (en) * 2005-01-07 2009-03-24 Alnylam Pharmaceuticals, Inc. RNAi modulation of RSV and therapeutic uses thereof
KR101425405B1 (ko) * 2009-07-17 2014-08-01 한림대학교 산학협력단 리포좀에 포집된 올리고뉴클레오타이드 및 에피토프를 포함하는 면역증강용 조성물
KR102435054B1 (ko) * 2012-08-01 2022-08-22 버베리안 노딕 에이/에스 재조합 변형된 백시니아 바이러스 앙카라(ankara) (mva) 호흡기 신시티알 바이러스(rsv) 백신
CN103243112A (zh) * 2013-05-16 2013-08-14 河北科星药业有限公司 预防大肠杆菌病的基因tsh-Ser及其制备以及利用其编码的蛋白

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1331355C (en) * 1986-04-21 1994-08-09 Bioenterprises Pty. Ltd Immunopotentation
FR2726577B1 (fr) * 1994-11-07 1997-01-31 Pf Medicament Procede d'obtention d'un peptide derive du virus respiratoire syncitial, polypeptide et bacterie l'exprimant, et leurs applications a titre de medicament
FR2726472B1 (fr) * 1994-11-07 1997-01-31 Pf Medicament Proteine porteuse a effet adjuvant, complexe immunogene la contenant, leur procede de preparation, sequence nucleotidique et vaccin
FR2766192B1 (fr) * 1997-07-17 2001-07-13 Pf Medicament Epitopes du vrs et anticorps les comportant, utiles dans le diagnostic et la therapie
NZ502626A (en) * 1997-07-18 2002-09-27 Connaught Lab Vaccines comprising a nucleic acid vector encoding the G protein of respiratory syncytial virus (RSV)
FR2776521B1 (fr) * 1998-03-27 2000-12-15 Pf Medicament Utilisation de conjugues p40 actifs par voie nasale

Also Published As

Publication number Publication date
CA2385404A1 (fr) 2001-03-29
MXPA02003132A (es) 2002-09-30
BR0014246A (pt) 2002-05-21
CN1379682A (zh) 2002-11-13
WO2001021203A9 (fr) 2002-05-10
JP2003528812A (ja) 2003-09-30
WO2001021203A1 (fr) 2001-03-29
FR2798857B1 (fr) 2003-06-06
EP1218029A1 (fr) 2002-07-03
FR2798857A1 (fr) 2001-03-30
AU7530100A (en) 2001-04-24

Similar Documents

Publication Publication Date Title
ZA200107102B (en) Intermittent administration of a growth hormone secretagogue.
IL148713A0 (en) Oral recombinant lactobacilli vaccines
HK1064958A1 (en) Vaccine against hpv
HUP0202885A3 (en) Vaccines
IL145044A0 (en) Vaccine
HUS1300072I1 (hu) Vakcina
PL351486A1 (en) Prrsv vaccines
AU6086300A (en) Recombinant envelope vaccine against flavivirus infection
AU6600300A (en) Pneumococcal vaccines
ZA200202175B (en) Use of an outer membrane protien a of an enterobacterium associated with a RSV immunogenic peptide for preparing vaccines for intranasal administration.
IL189736A0 (en) Vaccine adjuvants
AU5977700A (en) Vaccines
GB9901254D0 (en) Vaccines
IL148191A0 (en) Recombinant subunit vaccine
AU2913400A (en) Mage-3 derived immunogenic peptides presented by mhc of class ii and the use thereof
MXPA01010701A (es) Vacuna.
AU1703401A (en) Device for inhaling medicaments using supported pressure respiration
GB9913327D0 (en) Vaccine
EP1229042A4 (en) CYCLIC PEPTIDES AND AIDS VACCINES
AU2001251761A1 (en) Equine protozoal myeloencephalitis vaccine
GB9909072D0 (en) Vaccine
HK1045701A1 (zh) Fima菌毛基疫苗
AU2003204726A1 (en) Adjuvants for Use in Vaccines
GB9917981D0 (en) Viral vaccine
GB9909466D0 (en) Vaccines